Cite
HARVARD Citation
Pulte, E. et al. (2019). U.S. Food and Drug Administration Benefit‐Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission. Oncologist. pp. e188-e195. [Online].